Related Experiment Video
Updated: Mar 13, 2026
Author Spotlight: An Economic and Efficient Method for Quantitative Evaluation of Bone Microarchitecture in a Murine Osteoporosis Model
Published on: September 8, 2023
The Effect of TSH Suppression on Vertebral Trabecular Bone Scores in Patients With Differentiated Thyroid Carcinoma
Jae Hoon Moon1, Kyoung Min Kim1, Tae Jung Oh1
1Department of Internal Medicine, Seoul National University Bundang Hospital and Seoul National University College of Medicine, Seongnam-si, 13620, Korea; and.
Context:
The effect of thyrotropin (TSH) suppressive therapy on trabecular bone scores (TBSs) is unclear.
Objective:
The aim of this study was to investigate the effect of TSH suppression on vertebral TBSs of postmenopausal women with differentiated thyroid carcinoma (DTC).
Design, Setting, And Participants:
We conducted a retrospective cohort study including 273 postmenopausal women with DTC who had received TSH suppressive therapy. Bone mineral density (BMD) and TBSs at the lumbar spine were analyzed using dual-energy X-ray absorptiometry (DXA).
Major Outcome Measure:
The association between the parameters of TSH suppressive therapy and bone parameters was investigated.
Results:
Study subjects showed upper-normal free thyroxine levels and suppressed TSH at DXA evaluation. The mean duration of TSH suppression was 4.4 ± 2.9 years. Serum free T4 and TSH were not independently associated with lumbar spine BMD or TBS levels. Duration of TSH suppression was negatively correlated with lumbar spine TBS levels, but not with BMD. Longer duration of TSH suppression was independently associated with lower lumbar spine TBSs after adjusting for age, body mass index (BMI), and BMD. Lumbar spine TBSs were significantly lower in patients whose duration of TSH suppression was ≥5 years compared with those whose duration was <3 years after adjusting for age, BMI, and BMD.
Conclusions:
Longer duration of TSH suppression in postmenopausal DTC patients was associated with decreased vertebral bone strength by altering TBSs rather than BMD. TBSs should be considered when estimating vertebral bone fragility in postmenopausal DTC patients receiving long-term TSH suppressive therapy.
Related Concept Videos
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:20Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:18Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...
01:21Skeleton and Calcium Homeostasis
01:23The Thyroid Gland
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...